Behavidence, the Seed Funding for an NYC-based company that provides tools to monitor neurological and psychiatric disorders with artificial intelligence has reached $4.3M.
The round was led by Welltech Ventures, with participation from Arc Impact and Longevity Ventures.
The funds will be used by the company to further develop its machine-learning-based tools.
Behavidence, founded by Roy Cohen (CEO), Dr. Girish Shrinivasan and Dr. Janineellenberger (CMO), develops machine-learning-based tools to assist in remote monitoring and management for mental health conditions like depression, anxiety, ADHD, and other disorders using passive digital biomarkers. The company’s products can be used as a measurement-based outcome to monitor employee burnout, stress, predict relapse of conditions, screening, and remote monitoring for clinical interventions and comorbid conditions. These digital solutions are being adopted by tech, government, and health organizations.
Behavidence has secured over $1 million in contracts from customers all across the United States, Europe and Africa. Clients include the Department of Veterans Affairs and Discovery Health Insurance.